multidisciplinary team Side-icon

NCT06244771 - Frontier Medicines Corporation (PROSPER)

Brief Summary

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Official Title

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Conditions

Advanced Solid Tumors With KRAS G12C Mutations

Solid Tumor, Adult

Unresectable Solid Tumor

Metastatic Solid Tumor